The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Ozempic is already approved to treat T2D, for cardiovascular risk reduction ... worsening kidney disease and cardiovascular death in people with T2D and CKD. …as Rybelsus cuts MACE in type ...

A Maryland man has filed a lawsuit against the manufacturers of Ozempic, alleging that his use of the drug led to him ...

The Food and Drug Administration says it has seized several hundred units of fake versions of Ozempic. The drug maker Novo Nordisk told the FDA that the counterfeit 1-milligram injections were ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

GLP-1 drugs like Ozempic and Wegovy have been linked ... “We already know bariatric surgery cuts obesity-related cancer risk by about a third; these data suggest target GLP-1s may cut that ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity ... GLP-1 drugs cut 45% lower risk of dementia. Similar findings were published in ...